(secondQuint)Long Term Open Label Study in Narcolepsy With BF2.

649 (Pitolisant).

 In narcoleptic patients, results obtained in the previous studies showed that BF2.

649 reduced significantly the diurnal somnolence compared to placebo confirming its wakening effect against EDS and demonstrating its anti-cataplectic effect when administrated on an individual titration scheme established on basis of individual benefit/tolerance ratio.

This long-term safety pragmatic study will provide information about long-term treatment of BF2.

649, and also allow patients who satisfy of BF2.

649 treatment in previous or on-going studies of Bioprojet continuing to benefit this product.

This is an open-label, naturalistic pragmatic, prospective longitudinal uncontrolled, multi-centre international trial assessing the safety and effect of long-term therapy of BF2.

649 in treatment of excessive daytime sleepiness in narcolepsy, on 12-month follow-up.

.

 Long Term Open Label Study in Narcolepsy With BF2.

649 (Pitolisant)@highlight

This is a multicentric International Phase III,Long term open label study(12 months)assessing the long-term safety and efficacy of BF2.

649 (Pitolisant)in the treatment of Excessive Daytime Sleepiness (EDS) in narcoleptic patients with or without cataplexy.

